BYSI News and Press, BeyondSpring Inc. From 04/30/19

NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the...

- Significant Clinical Data Generated for Plinabulin - - On Track to Submit New Drug Applications (NDAs) for Plinabulin to China’s National Medical Products Administration (NMPA) for Both Non-Small Cell Lung Cancer (NSCLC) and Chemotherapy-Induced Neutropenia (CIN) in Q4 2019...

NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2018 financial results and host an operat...

BeyondSpring ( BYSI ) is a China-originated undercovered stock in late clinical stage for its lead drug candidate plinabulin in chemotherapy-induced neutropenia ((CIN)). CIN is a common side effect in chemotherapy-treated cancer patients. Chemotherapy destroys white blood cells, specifically n...

NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference ...

NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present a promising new strategy for cancer treatment involving the ability ...

NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present novel data relevant to predictive biomarkers for patient selection f...

NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will present clinical data on its lead asset, Plinabulin, during a poster present...

NEW YORK , March 05, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, presented new clinical results from its Study 106 program in the prevention of chemotherapy induced neutropenia (...

New data from a Phase 2 clinical trial, Study 106 , evaluating BeyondSpring's ( BYSI +0.1% ) lead drug Plinabulin compared to Amgen's ( AMGN +0.1% ) Neulasta (pegfilgrastim) in reducing the duration of severe neutropenia (abnormally low levels of a type of white blood cell) in certai...